Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 4/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781773 | 0.88 | TAS1R3 (0.40) | PARP10TAS1R3TAS1R1TAS1R2SRC | |
| SCHEMBL7654914 | 0.83 | SRC (0.51) | SRC | |
| SCHEMBL7654125 | 0.82 | SRC (0.58) | PARP10SRCPARP15 | |
| SCHEMBL7654129 | 0.82 | SRC (0.58) | PARP10SRCPARP15 | |
| SCHEMBL7240357 | 0.82 | SRC (0.44) | SRC | |
| SCHEMBL20533142 | 0.80 | DRD2 (0.41) | TAS1R3TAS1R1TAS1R2BDKRB1ALDH1A1 | |
| SCHEMBL20533140 | 0.80 | DRD2 (0.41) | TAS1R3TAS1R1TAS1R2BDKRB1ALDH1A1 | |
| SCHEMBL20683057 | 0.80 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2BDKRB1 | |
| SCHEMBL26073271 | 0.80 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2BDKRB1 | |
| SCHEMBL16809810 | 0.79 | KMT2A (0.44) | TAS1R3TAS1R1TAS1R2CACNA1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6482852-B2 | UE TREATING PROLIFERATIVE DISEASE, CANCER, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, ALLERGIES, OR CARDIOVASCULAR DISEASE; INHIBITION OF SH2-MEDIATED SIGNALING | ARIAD PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | PARP10 2644/4885TAS1R3 3142/4885TAS1R1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.